ZZZhiyu Zhang

Zhiyu Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zhiyu Zhang has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Composite Inflammatory Score for Predicting Progression‐Free Survival in Metastatic Clear Cell Renal Cell Carcinoma Treated With First‐Line Toripalimab Plus Axitinib

    by Yun‐Feng Wu, Jing‐Suo Wang, Chuan‐Ao Zhang, Fan Zhang, Zhi‐Yu Zhang

    Routine inflammatory and nutritional markers may help stratify progression risk in metastatic clear cell renal cell carcinoma during immunotherapy‐based treatment. This single‐center retrospective study included 237 patients who received first‐line toripalimab plus axitinib therapy. Ten indices were natural‐log transformed and standardized, and domain‐based selection yielded a compact composite inflammatory score (COMP‐IS), which was internally validated using 1000 full‐pipeline bootstrap resamples. The primary endpoint was progression‐free survival (PFS). During a median follow‐up of 19.84 months for PFS, 124 events occurred. COMP‐IS comprised the neutrophil‐to‐lymphocyte ratio, C‐reactive protein‐to‐albumin ratio (CAR), and prognostic nutritional index. After adjusting for the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) score, each standard deviation increase in COMP‐IS was associated with shorter PFS (hazard ratio, 3.48; 95% confidence interval, 2.74–4.42). The apparent concordance index (C‐index) for COMP‐IS was 0.767, with a bootstrap‐corrected C‐index of 0.755, compared with corrected C‐indices of 0.694 for CAR and 0.565 for the IMDC score. Adding IMDC to COMP‐IS resulted in a corrected C‐index of 0.756. In an exploratory post hoc comparison, the published Meet‐URO risk groups had an apparent C‐index of 0.593. COMP‐IS demonstrated prognostic discrimination for PFS in this cohort; however, only internal validation was performed. Its clinical utility therefore remains uncertain, and independent external validation and prospective evaluation are needed before routine clinical use.

  • Open Access

    CD276 promotes immune evasion in clear cell renal cell carcinoma via NF-κB-IL-6-STAT3 signaling crosstalk

    by Fan Zhang, Jingsuo Wang, Chuanao Zhang, Jun Ouyang, Zhiyu Zhang

    Background: Clear cell renal cell carcinoma (ccRCC) exhibits prominent immune infiltration and inflammatory signaling, yet the tumor-intrinsic mechanisms that promote immune evasion remain incompletely defined. CD276/B7-H3 is linked to an unfavorable prognosis in ccRCC, but its involvement in regulating inflammatory immune suppression requires clarification. This study aimed to determine whether tumor-cell CD276 drives nuclear factor kappa B (NF-κB)-interleukin (IL)-6-signal transducer and activator of transcription 3 (STAT3) signaling and macrophage-dependent immune evasion in ccRCC. Methods: The Cancer Genome Atlas (TCGA)-Kidney Renal Clear Cell Carcinoma cohort (KIRC) data were analyzed to assess CD276 expression, prognosis, and immune-related signatures. Stable CD276-knockdown 786-O and Caki-1 cells were generated using shRNA. Cell proliferation, invasion, NF-κB activation, cytokine secretion, and STAT3 signaling were evaluated using Cell Counting Kit-8 (CCK-8), Transwell assays, Western blotting, immunofluorescence, luciferase reporter assays, reverse-transcription quantitative polymerase chain reaction (RT-qPCR), and enzyme-linked immunosorbent assay (ELISA). Tumor-conditioned media were applied to THP-1-derived macrophages to examine STAT3-dependent polarization. Macrophage-T-cell co-culture assays were used to assess T-cell activation, cytokine secretion, and proliferation. Results: CD276 was highly expressed in ccRCC tissues and was associated with poorer overall survival (OS) and enrichment of macrophage-related and IL-6-JAK-STAT3 immune signatures. CD276 knockdown inhibited ccRCC cell proliferation and invasion, reduced NF-κB p65 nuclear translocation and transcriptional activity, and decreased IL-6 production. CD276 silencing also attenuated STAT3 phosphorylation in tumor cells and macrophages. Conditioned media from CD276-knockdown cells suppressed CD206⁺CD163⁺ macrophage polarization, decreased ARG1 and IL-10 expression, and increased iNOS expression. Functionally, macrophages exposed to CD276-deficient tumor media showed reduced suppression of CD3⁺ T-cell activation, interferon gamma (IFN-γ) and IL-2 secretion, and proliferation. Recombinant IL-6 restored, whereas STAT3 inhibition or IL-6 neutralization diminished, these effects. Conclusions: CD276 promotes ccRCC immune evasion by activating an NF-κB-IL-6-STAT3 signaling axis that drives immunosuppressive macrophage polarization and T-cell dysfunction.

  • Open Access

    Association between duration of neoadjuvant hormonal therapy and prostate-specific antigen response and pathological outcomes in high-risk prostate cancer undergoing robot-assisted radical prostatectomy

    by Jingsuo Wang, Yunfeng Wu, Chuanao Zhang, Jun Ouyang, Fan Zhang, Zhiyu Zhang

    Purpose: The optimal duration of neoadjuvant hormonal therapy (NHT) for high-risk prostate cancer remains controversial. In this study, we evaluated the association between NHT duration and prostate-specific antigen (PSA) kinetics as well as pathological outcomes in patients who underwent extraperitoneal robot-assisted radical prostatectomy. Methods: We retrospectively analyzed the data of 72 patients with high-risk prostate cancer who received NHT followed by extraperitoneal robot-assisted radical prostatectomy with pelvic lymph node dissection at a tertiary hospital in 2025. Patients were stratified into the short-term (NHT, ≤3 months; n=41) and long-term (NHT, >3 months; n=31) groups. PSA response, pathological features, and perioperative outcomes were compared between the two groups. Results: The PSA nadir was significantly lower in patients who underwent long-term NHT than in those who underwent short-term NHT (median 0.02 vs. 0.23 ng/mL). The proportions of patients in whom PSA levels of <0.1 ng/mL (67.74% vs. 29.27%) and <0.2 ng/mL (83.87% vs. 41.46%) were achieved were significantly higher in the long-term group. Pathological analyses demonstrated a significantly lower incidence of extraprostatic extension in patients undergoing long-term NHT (38.71% vs. 70.73%). Operative time and intraoperative blood loss were similar between the groups. Conclusion: In patients with high-risk prostate cancer, undergoing NHT for longer than 3 months was associated with greater suppression of PSA and more favorable pathological outcomes. Particularly, we observed a reduced incidence of extraprostatic extension and no increase in perioperative morbidity. Achieving a substantial PSA response during NHT may be useful as an indicator for optimizing the timing of surgical intervention.

  • Open Access

    Development and validation of a nomogram for predicting sperm retrieval success in patients with non-obstructive azoospermia undergoing testicular sperm aspiration

    by Qi Zhou, Xuanping Lu, Yanyu Zhong, Xiaowei Fan, Fan Zhang, Jun Ouyang, Weiqin Zhou, Zhiyu Zhang

    Non-obstructive azoospermia (NOA) is a major cause of male infertility, characterized by impaired spermatogenesis. Testicular sperm aspiration (TESA) is widely used for sperm retrieval in assisted reproduction, but predicting its success remains challenging. This study developed and validated a nomogram for predicting sperm retrieval outcomes in patients with NOA undergoing TESA. We retrospectively analyzed 548 patients with NOA who underwent TESA at the Andrology Department of The First Affiliated Hospital of Soochow University between January 2010 and January 2025. Patients were classified into sperm-positive (n=284) and sperm-negative (n=264) groups. Clinical, demographic, hormonal, biochemical, and imaging data were collected. Univariate analysis identified potential predictors, which were further assessed using multivariate logistic regression. Independent predictors were incorporated into a nomogram. Model performance was evaluated using calibration plots, receiver operating characteristic curve analysis, and decision curve analysis (DCA). Multivariate analysis identified larger testicular volume [odds ratio (OR): 0.707/mL, 95% confidence interval (CI): 0.659–0.759/mL, P2 =5.1207, P=0.74) and excellent discrimination (area under the curve: 0.842, 95% CI: 0.809–0.874), outperforming individual predictors. DCA confirmed superior clinical net benefit of the model over single variables. Our results suggest that the validated, noninvasive, and clinically applicable model may enhance preoperative counseling, optimize treatment strategies, and support individualized patient management.


  • Open Access

    Neoadjuvant chemoradiotherapy plus programmed cell death protein-1 blockade versus chemoradiotherapy alone for muscle-invasive bladder cancer: a real-world comparative study

    by Fan Zhang, Jingsuo Wang, Yanhang Yu, Chuanao Zhang, Jun Ouyang, Zhiyu Zhang

    Introduction: Muscle-invasive bladder cancer (MIBC) has a high risk of recurrence and mortality despite radical cystectomy. Neoadjuvant chemoradiotherapy (NACRT) offers has been investigated as a bladder-preserving strategy in selected patients; however, in this study, all patients underwent radical cystectomy following NACRT, and programmed cell death protein-1 (PD-1) inhibitors have shown antitumor activity in urothelial carcinoma. Combining NACRT with PD-1 blockade may enhance tumor response; however, its pathological benefits and short-term safety remain unclear. This study aimed to compare pathological response and short-term safety between NACRT alone and NACRT combined with PD-1 blockade (NACRT + PD-1) in patients with MIBC. Methods: A retrospective review was conducted for 59 consecutive patients with MIBC (cT2–T4aN0M0) treated at the First Affiliated Hospital of Soochow University between January 2021 and December 2024. Twenty-seven patients received NACRT alone, and 32 received NACRT plus a PD-1 inhibitor—toripalimab (n=18) or tislelizumab (n=14). Chemotherapy comprised gemcitabine 1,000 mg/m² (days 1 and 8) and cisplatin 70 mg/m² (days 2–3) every 21 days for ≥3 cycles. Intensity-modulated pelvic radiotherapy delivered 45 Gy in 25 fractions plus a weekly boost (10 Gy in five fractions) to the bladder. The PD-1 antibody (toripalimab 200 mg or tislelizumab 240 mg) was infused on day 8 of each cycle. The primary endpoints were pathological downstaging rate (PDR, ≤ypT1/Tis/TaN0M0) and pathological complete response rate (PCRR, ypT0N0M0). The secondary endpoint was treatment-related adverse events (AEs) graded using the Common Terminology Criteria for Adverse Events version 5.0. Group comparisons used χ², Fisher’s exact, or non-parametric tests as appropriate (two-sided, α=0.05). Results: Baseline demographics and clinical characteristics were balanced between the groups (all p > 0.05). After radical cystectomy, pathological stage distribution did not differ significantly (p > 0.05). The PDR was 74.07% (20/27) in the NACRT group and 87.50% (28/32) in the NACRT + PD-1 group (p=0.187). The PCRR increased from 44.44% (12/27) with NACRT alone to 71.88% (23/32) with PD-1 addition (p=0.033). Toripalimab and tislelizumab achieved comparable PDRs (83.33% vs . 92.86%, p=0.613) and PCRRs (66.67% vs . 78.57%, p=0.694). No grade ≥4 AEs or treatment-related deaths occurred, and AE frequencies were similar between groups (all p > 0.05). Conclusion: NACRT combined with PD-1 blockade significantly improved PCRR without increasing toxicity in patients with MIBC. These findings support conducting a prospective single-arm phase II multicenter trial to confirm potential long-term survival benefits.

  • Open Access

    Development of a radiomics and clinical feature-based nomogram for preoperative prediction of pathological grade in bladder cancer

    by Qi Zhou, Lu Ma, Yanhang Yu, Chuanao Zhang, Jun Ouyang, Caiping Mao, Zhiyu Zhang

    Introduction: This study aimed to develop a preoperative predictive model for pathological grading of bladder urothelial carcinoma by integrating multi-parameter, thin-slice enhanced computed tomography (CT) texture features with relevant clinical indicators.Methods: CT images and clinical data were retrospectively collected from 372 individuals diagnosed with bladder urothelial carcinoma at our institution between January 2015 and October 2020. The cohort was categorized into high-grade urothelial carcinoma (HGUC; n = 190) and low-grade urothelial carcinoma (LGUC; n = 182). Participants were randomly assigned to a training group (n = 259) and a validation group (n = 113) in a 7:3 ratio. Regions of interest (ROIs) were delineated on all enhanced CT images using 3D-Slicer software, and 1,223 texture features encompassing first-order, second-order, high-order, and filtered attributes were extracted. Features with an intraclass correlation coefficient (ICC) above 0.75 were retained for further analysis via least absolute shrinkage and selection operator (LASSO) regression. A logistic regression model was constructed based on the selected features to develop a clinical prediction tool. The model’s performance was evaluated using the concordance index (C-index), calibration curve, receiver operating characteristic (ROC) curve, and decision curve analysis (DCA).Results: Eleven radiomics features demonstrated significant associations with the pathological grade of bladder urothelial carcinoma. Among the models evaluated, the logistic regression model exhibited the highest discriminative power, with an area under the curve (AUC) of 0.858. Multivariate analysis identified age and proteinuria as independent predictors. The integrated model, incorporating both clinical and imaging features, outperformed models based on clinical or radiomic data alone (AUC = 0.864).Conclusion: This study presents the first CT-based nomogram that integrates multiparametric radiomic features with comprehensive clinical indicators to preoperatively predict pathological grade in bladder urothelial carcinoma. The model offers a robust, accurate, and non-invasive tool that can facilitate individualized treatment planning and enhance clinical decision-making.


  • Open Access

    Clinicopathological Characteristics and Prediction of Postoperative Mortality Risk in Patients with Non-metastatic Sarcomatoid Renal Cell Carcinoma

    by Lian Fang, Zhiyu Zhang, Ouyang Song, Yufeng Hou, Hujuan Yang, Jun Ouyang, Xuefeng Zhang, Nan Wang, Shicheng Sun

    Introduction: Sarcomatoid renal cell carcinoma (sRCC) is rare but highly aggressive and is associated with poor prognosis and limited treatment responsiveness. Despite several studies investigating its clinicopathological features, existing research is often limited by small sample sizes and short follow-up periods, and currently, no prognostic risk model is specific to patients with non-metastatic sRCC. This study aimed to investigate the clinicopathological characteristics of patients with non-metastatic sRCC and develop a predictive model for postoperative mortality risk. Methods: In this retrospective study, we analyzed the clinical data of 45 patients diagnosed with non-metastatic sRCC who underwent surgical treatment at our institution's Department of Urology, between January 2008 and June 2024. These patients were compared with 527 patients with non-sarcomatoid renal cell carcinoma (non-sRCC). The primary endpoint was death, and the exact cause of death was recorded. Routine postoperative examinations and treatment details were documented through outpatient and inpatient electronic medical record systems. Results: The results indicated significant differences in body mass index, hypertension, surgical approach, nephrectomy type, surgical duration, maximum tumor diameter, tumor necrosis, T stage, and Ki-67 expression between patients with sRCC and those with non-sRCC ( P < 0.05). Survival analysis revealed that the cancer-specific survival (CSS) for patients with sRCC was significantly lower than that for patients with non-sRCC ( P < 0.001). Cox univariate and multivariate analyses identified maximum pathological tumor diameter, T stage, and high Ki-67 expression as independent risk factors. Based on these factors, we developed a postoperative mortality risk prediction model for patients with sRCC, with the calibration curves demonstrating a good fit of the model. Conclusions: The proposed model is designed for patients with non-metastatic sRCC. It has potential clinical application value, aiding in the identification of high-risk patients and providing guidance for individualized treatment and close follow-up.

  • Open Access

    Identification of Enzalutamide‐Related Genes for Prognosis and Immunotherapy in Prostate Adenocarcinoma

    by Lian Fang, Zongming Jia, Tao Zou, Ouyang Song, Jun Ouyang, Yufeng Hou, Zhiyu Zhang, Xuefeng Zhang

    Enzalutamide is classified as a novel antiandrogen medication; however, the majority of patients ultimately develop resistance to it. Consequently, conducting an in‐depth investigation into potential targets of enzalutamide is essential for addressing the drug resistance observed in patients and for facilitating the discovery of new therapeutic targets. The SwissTargetPrediction database was used to identify targets linked to enzalutamide and to assess these targets in the prostate adenocarcinoma (PRAD) dataset sourced from the TCGA database. By employing various datasets and applying different machine learning methods for clustering, researchers constructed and validated both diagnostic and prognostic models for PRAD. A correlation analysis with the androgen receptor revealed TDP1 as the gene most significantly associated with enzalutamide. In addition, this study examined the relationship between TDP1 and immune infiltration. The expression levels of TDP1 and its prognostic correlation in PRAD patients were validated through immunofluorescence staining of 60 PRAD tissue specimens. Cluster analysis revealed a notable correlation among the 24 genes related to enzalutamide with regard to both prognosis and immune infiltration in PRAD patients. The diagnostic model, which incorporates various machine learning techniques, exhibits robust predictive ability for PRAD diagnosis, while the prognostic model employing the LASSO algorithm has also shown encouraging outcomes. Among the various prognostic genes linked to enzalutamide, TDP1 stands out as an important indicator of prognosis. Furthermore, immunofluorescence experiments confirmed that an increased expression of TDP1 is associated with a worse prognosis in patients with PRAD. Our results underscore the substantial potential of TDP1 as a novel diagnostic and prognostic biomarker for individuals diagnosed with PRAD.

  • Open Access

    Development of a predictive nomogram for testicular sperm extraction outcomes in patients with non-obstructive azoospermia using testicular volume, follicle-stimulating hormone levels, and testosterone levels as key parameters

    by Qi Zhou, Caiping Mao, Jun Ouyang, Zhiyu Zhang

    Background: Non-obstructive azoospermia (NOA) is a prevalent cause of male infertility, characterized by the lack of sperm in the ejaculate due to impaired spermatogenesis. Accurate prediction of testicular sperm extraction (TESE) outcomes is pivotal for counseling and managing patients, yet remains challenging due to variability in clinical presentations. This study aimed to establish a predictive model for TESE outcomes in patients with NOA. Methods: We retrospectively analyzed 425 patients who visited the Andrology Outpatient Clinic of the First Affiliated Hospital of Soochow University between January 2010 and January 2024. Of these, 216 had positive sperm retrieval, and 209 had negative outcomes. We compared testicular volume, reproductive hormone levels, and other clinical parameters between two groups. Multivariate logistic regression was used to identify independent risk factors that were used to establish a predictive nomogram. A calibration curve was used to evaluate the model’s fit, whereas receiver operating characteristic (ROC) curves and decision curve analysis (DCA) were used to assess diagnostic effectiveness and net benefit. Results: The differences were significant in serum follicle-stimulating hormone (FSH) (PConclusions: In patients with NOA, low testicular volume, low testosterone levels, and high FSH levels were independent risk factors for unsuccessful TESE. The predictive nomogram provided excellent predictive power for positive TESE outcomes.


  • Open Access

    Correction to: Marker Ki-67 is a potential biomarker for the diagnosis and prognosis of prostate cancer based on two cohorts

    by Zhen Song, Qi Zhou, Jiang-Lei Zhang, Jun Ouyang, Zhi-Yu Zhang

    This is an erratum to the published paper titled “Marker Ki-67 is a potential biomarker for the diagnosis and prognosis of prostate cancer based on two cohorts”. We have discovered that Reference 4 was cited incorrectly. We sincerely apologize for this inadvertent error. Please note that these corrections do not impact our results.